Related Experiment Videos
Preclinical evaluation of recombinant human interleukin-4
J B Cornacoff1, K A Gossett, T A Barbolt
1Sterling Winthrop Pharmaceuticals Research Division, Rensselaer, NY 12144.
Toxicology Letters
|December 1, 1992
Summary
Recombinant human interleukin-4 (rhuIL-4) in monkeys caused coagulopathy and vascular lesions, with effects reversing post-treatment. Antibody development in monkeys, unlike humans, may influence outcomes.
Area of Science:
- Immunology
- Toxicology
- Oncology
Background:
- Recombinant human interleukin-4 (rhuIL-4) exhibits anti-cancer properties.
- Primate-specific rhuIL-4 requires evaluation in non-human primates for cancer immunotherapy development.
Purpose of the Study:
- To assess the safety and biologic effects of rhuIL-4 in cynomolgus monkeys.
- To support clinical development of rhuIL-4 for cancer immunotherapy.
Main Methods:
- Cynomolgus monkeys received subcutaneous injections of rhuIL-4 at varying doses (0-12.5 µg/kg BID) for one month.
- Clinical chemistry, hematology, and histopathology were evaluated.
- Antibody titers against rhuIL-4 were measured using ELISA.
Main Results:
- rhuIL-4 administration led to consumptive coagulopathy, increased granulopoiesis, testicular atrophy, and vascular lesions.
- Adverse effects were dose-related and generally reversible.
- Monkeys developed antibodies to rhuIL-4, a response not observed in humans.
Conclusions:
- rhuIL-4 induced significant toxicities in cynomolgus monkeys, including hematologic and vascular changes.
- The development of anti-rhuIL-4 antibodies in monkeys may influence treatment outcomes and differs from human responses.
- Findings suggest careful monitoring for adverse effects in clinical trials.